Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
at www.tipranks.com (Mon, 30-Mar 6:26 AM)
FDA Approves KRESLADI: Rocket Pharmaceuticals Achieves Major Milestone in Ultra-Rare Pediatric Immunodeficiency
Market Chameleon (Fri, 27-Mar 7:05 AM)
Rocket Pharmaceuticals Strengthens Position in Cardiovascular Gene Therapy with Reduced Losses and Advance in Key Programs
Market Chameleon (Fri, 27-Feb 10:34 AM)
